Blood Neoplasia
Издатель: Elsevier · ISSN 2950-3280 · 100 статей
- Loss of HTLV-1–specific CD8+ T-cell immunity in virus carriers predisposed to adult T-cell leukemia/lymphoma
- Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma
- Myeloid cell–mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference
- Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens
- Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death
- Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report
- Genomic features of clonal hematopoiesis–associated genes in primary and CAR T-cell–related secondary T-cell malignancies
- CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates
- Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment
- The Goldman odyssey for a cure in patients with chronic myeloid leukemia
- Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models
- The KDM-family inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing a ferroptosis-like phenotype
- CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?
- Real-world pharmacokinetics of venetoclax in patients with acute myeloid leukemia in Japan
- Post-transplant outcomes after intensive chemotherapy versus hypomethylating agent/venetoclax in acute myeloid leukemia
- Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study
- Hypomethylating agents–venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT
- Self-supervised learning can distinguish myelodysplastic neoplasms from clinical mimics using bone marrow biopsies
- Expression of RUNX1::RUNX1T1 deregulates the proteome, induces C/EBPβ suppression, and blocks myeloid differentiation
- Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS
- ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma
- Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent IDH1 mutation
- Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia
- Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia
- Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden
- Liquid biopsy for molecular profiling in cutaneous T-cell lymphoma: a pilot feasibility study
- Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial
- Epigenetics as a mechanism of lineage extinction and relapse of B-cell lymphoma treated with CD19 CAR T-cell therapy
- Ten-day decitabine vs “3+7” in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21
- Clinical features and outcomes of MPN with concurrent MPL and JAK2/CALR Mutations